대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Renoprotective Effects of Empagliflozin in Obesity-Related Glomerulopathy Mice through Regulation the Gut-Kidney Axis
저자	Lei Lei
출판정보	2024; 2024(1):
키워드
초록	Objectives: The rising incidence of obesity-related glomerulopathy (ORG) poses a significant threat to public health. Sodium-glucose co-transporter-2 (SGLT2) inhibitors effectively reduce body weight and total fat mass in obese individuals, as well as to halt the progression of ORG. However, the underlying mechanism of the renoprotective effects of SGLT2 inhibitors in ORG remains unclear. Methods: A high-fat diet-induced ORG model was established using C57BLJ mice. The mice were divided into three groups: normal chow diet (NCD group), high-fat diet (HFD) mice treated with placebo (ORG group), and HFD mice treated with Empagliflozin (EMPA) (EMPA group). 16S ribosomal RNA gene sequencing of feces, and metabolites of kidney, feces, liver and serum were analyzed. Results: We found that the levels of the urinary albumin creatinine ration, cholesterol, triglyceride and diameter of glomerulus increased in ORG mice compared to NCD mice (all p < 0.0001); EMPA treatment alleviated these parameters (all p < 0.05). Multi-tissues metabolomics analysis revealed lipid metabolic reprogramming in ORG mice, and EMPA treatment altered the metabolic profiles. Furthermore, MetOrigin analysis unveiled a close association between EMPA-related lipid metabolic pathways and gut microbiota alterations, characterized by reduced abundances of Firmicutes and Desulfovibrio, and increased abundance of Akkermansia (all p < 0.05). Conclusions: The metabolomic homeostasis of ORG mice was disrupted, especially in lipid metabolism. This disruption is closely associated with gut microbiota and is related to the progression of ORG. EMPA treatment improved kidney function and morphology by regulating lipid metabolic through the gut-kidney axis.
원문(PDF)	PDF 원문보기

목록

위로가기